{"id":51216,"date":"2022-11-24T11:02:05","date_gmt":"2022-11-24T10:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pediatric-vaccines-global-markets-report-2022-impacts-of-covid-19-market-revenue-data-for-2020-and-2021-estimates-for-2022-and-cagr-projections-through-2027-researchandmarkets-com\/"},"modified":"2022-11-24T11:02:05","modified_gmt":"2022-11-24T10:02:05","slug":"pediatric-vaccines-global-markets-report-2022-impacts-of-covid-19-market-revenue-data-for-2020-and-2021-estimates-for-2022-and-cagr-projections-through-2027-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pediatric-vaccines-global-markets-report-2022-impacts-of-covid-19-market-revenue-data-for-2020-and-2021-estimates-for-2022-and-cagr-projections-through-2027-researchandmarkets-com\/","title":{"rendered":"Pediatric Vaccines Global Markets Report 2022: Impacts of COVID-19, Market Revenue Data for 2020 and 2021, Estimates for 2022, and CAGR Projections through 2027 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Pediatric Vaccines: Global Markets”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market’s drivers, challenges and opportunities. The report also covers market projections through 2027 and estimates market shares for key players, as well as pediatric vaccines by type and by application. The report also discusses the impact of the COVID-19 pandemic on this market.\n<\/p>\n

\nVaccines are one of the most significant advances in global health and are the most cost-effective strategy to reduce child mortality. Vaccines help to prevent 2 million to 3 million deaths each year. Yet, each year millions of children are left out of vaccine distribution, mostly in less developed regions.\n<\/p>\n

\nThe COVID-19 pandemic also affected the pediatric immunization schedules. As per WHO, the vaccine coverage dipped for major vaccines such as those for diphtheria, tetanus and pertussis, measles, mumps and varicella, BCG and hepatitis. The dip in coverage led to outbreaks of vaccine-preventable diseases in some regions. As a result, organizations such as Gavi, UNICEF and WHO have started taking measures to increase the pediatric vaccine coverage.\n<\/p>\n

\nPneumococcal, meningococcal, combination vaccine (hexavalent vaccine) and COVID-19 have been approved. In 2021, vaccines such as Comirnaty from Pfizer\/BioNTech, Spikevax from Moderna, CoronaVac from Sinovac, vaccines from the China National Pharmaceutical Group (Sinopharm), ZyCoV-D from Zydus Cadila (India) and Covaxin from Bharat Biotech (India) have been approved for the pediatric population.\n<\/p>\n

\nOther drivers contributing to the market include government support, growing investments and R&D budgets, collaboration agreements, and the increasing incidence and burden of diseases.\n<\/p>\n

\nIn this report, the market is segmented based on technology, disease type and region. The North American market currently holds the highest market share.\n<\/p>\n

\nCompany profiles of major players within the industry, including Pfizer, Abbott Laboratories, Merck & Co., GlaxoSmithKline, Sanofi SA and AstraZeneca\n<\/p>\n

\nReport Includes<\/strong>\n<\/p>\n